Pharmacy Medical News about Diabetes

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp Therapy in CKD Patients With Type-2 Diabetes
Amgen, 08/26/09

Amgen announced that in a large, randomized, double–blind, placebo–controlled, Phase 3 study of patients with chronic kidney disease, anemia and type–2 diabetes, treatment of anemia with Aranesp to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment. The two primary endpoints were a composite of time to all–cause mortality or cardiovascular morbidity and a composite of time to all–cause mortality or chronic renal replacement therapy.

<< Previous
Golimumab effective for RA when other TNF-alpha inhibitors fail

Next >>
Pharmacokinetics and Pharmacodynamics of Prasugrel, a...